NASDAQ:LIFE
aTyr Pharma Stock News
$1.60
-0.0200 (-1.23%)
At Close: Apr 24, 2024
aTyr Pharma to Present at BIO CEO & Investor Conference
01:00pm, Monday, 07'th Feb 2022 GlobeNewswire
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, which is being held February 14 – 17, 2022, at the Marriott Marquis in New York, NY.
aTyr Pharma to Present at BIO CEO & Investor Conference
08:00am, Monday, 07'th Feb 2022
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path
aTyr Pharma''s lung disease drug ATYR1923 named efzofitimod
02:16pm, Thursday, 13'th Jan 2022 Seeking Alpha
aTyr Pharma <> said the U.S. Adopted Names ((USAN)) Council and the World Health Organizations ((WHO)) International Nonproprietary Name ((INN)) expert committee have selected
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
01:03pm, Thursday, 13'th Jan 2022 GlobeNewswire Inc.
Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022 Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of "efzofitimod" as Nonproprietary Name
01:03pm, Thursday, 13'th Jan 2022 Benzinga
SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ: LIFE ), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the United States Adopted Names (USAN) Council and the World Health Organization''s (WHO) International Nonproprietary Name (INN) Expert Committee have selected the nonproprietary name efzofitimod for ATYR1923, a novel immunomodulator targeting neuropilin-2 (NRP2), in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease. "aTyr is working to develop a new class of medicines based on extracellular tRNA synthetase biology, and the assignment of the nonproprietary name efzofitimod for ATYR1923 is an important step as we continue to advance this potentially disease-modifying immunomodulator to its next stage of development," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Efzofitimod is engineered from a naturally occurring splice variant of histidyl-tRNA synthetase, which is enriched in lung tissue and we believe plays a role in the natural regulation of the immune system.
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
01:00pm, Thursday, 06'th Jan 2022 Benzinga
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ: LIFE ), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for its lead therapeutic candidate, ATYR1923, for the treatment of sarcoidosis. ATYR1923 is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states. Clinical proof-of-concept was recently established for ATYR1923 in a Phase 1b/2a study in patients with pulmonary sarcoidosis, the main form of the disease, and the company expects to initiate a registrational trial in this indication this year. The FDA''s Office of Orphan Drug Products grants orphan status to support the development of medicines for patients with unmet needs for rare disorders affecting fewer than 200,000 people in the United States.
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
01:03pm, Tuesday, 04'th Jan 2022 GlobeNewswire Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pa
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
08:03am, Tuesday, 04'th Jan 2022
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological path
aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
09:46am, Tuesday, 28'th Dec 2021
aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
01:02pm, Friday, 24'th Dec 2021 GlobeNewswire Inc.
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pa
Zacks: Brokerages Expect aTyr Pharma, Inc. (NASDAQ:LIFE) Will Post Quarterly Sales of $7.50 Million
02:00am, Saturday, 11'th Dec 2021 Dakota Financial News
Wall Street brokerages predict that aTyr Pharma, Inc. (NASDAQ:LIFE) will post $7.50 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for aTyr Pharmas earnings. The highest sales estimate is $10.00 million and the lowest is $5.00 million. aTyr Pharma reported sales of $2.05 million in the []
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
01:00pm, Friday, 10'th Dec 2021 GlobeNewswire Inc.
Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. Novel engineering approach accelerates generation of new antibody candidates from tRNA synth
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
08:00am, Friday, 10'th Dec 2021
Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. Novel engineering approach accelerates generation of new antibody candidates from tRNA synth
-$0.24 Earnings Per Share Expected for aTyr Pharma, Inc. (NASDAQ:LIFE) This Quarter
10:28pm, Wednesday, 08'th Dec 2021 Dakota Financial News
Analysts forecast that aTyr Pharma, Inc. (NASDAQ:LIFE) will report earnings of ($0.24) per share for the current quarter, according to Zacks. Two analysts have issued estimates for aTyr Pharmas earnings, with estimates ranging from ($0.44) to $0.12. aTyr Pharma reported earnings of ($0.47) per share in the same quarter last year, which indicates a positive []
Zacks: Analysts Anticipate aTyr Pharma, Inc. (NASDAQ:LIFE) to Post -$0.24 Earnings Per Share
11:34am, Saturday, 04'th Dec 2021 Transcript Daily
Equities analysts expect that aTyr Pharma, Inc. (NASDAQ:LIFE) will report earnings per share (EPS) of ($0.24) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for aTyr Pharmas earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at $0.12. aTyr Pharma reported earnings []